Sage Therapeutics DEF 14A: Executive Compensation Details
| Field | Detail |
|---|---|
| Company | Sage Therapeutics, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Sage Therapeutics DEF 14A out: exec comp details for 2024, including equity awards for Greene & Jonas.
AI Summary
Sage Therapeutics, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key personnel such as Barry E. Greene and Jeffrey M. Jonas, M.D., with data points for fiscal years 2020 through 2024.
Why It Matters
This filing provides transparency into how Sage Therapeutics compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: low — This is a routine filing providing information on executive compensation and does not indicate any immediate financial or operational risks.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for executive compensation)
- 2020-2024 — Data Range (Years covered by equity award information)
Key Players & Entities
- Sage Therapeutics, Inc. (company) — Filer of the DEF 14A
- Barry E. Greene (person) — Executive mentioned in compensation details
- Jeffrey M. Jonas, M.D. (person) — Executive mentioned in compensation details
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for an upcoming annual or special meeting of security holders. It contains detailed information about matters to be voted on, including executive compensation, director nominations, and other corporate governance issues.
Who are the key individuals whose compensation is detailed in this filing?
The filing specifically mentions Barry E. Greene and Jeffrey M. Jonas, M.D., in the context of equity awards and compensation data for various fiscal years.
What types of compensation are typically disclosed in a DEF 14A filing?
DEF 14A filings typically disclose various forms of executive compensation, including base salary, bonuses, stock awards, option awards, non-equity incentive plan compensation, and changes in the value of pension or deferred compensation.
What is the significance of the 'ecd:PeoMember' tag in the filing?
The 'ecd:PeoMember' tag likely indicates that the individual is considered a 'principal executive officer' or a 'named executive officer' for the purposes of the compensation disclosure tables within the filing.
What is the filing date of this DEF 14A?
This DEF 14A filing was made on April 24, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 by Barry E. Greene regarding Sage Therapeutics, Inc..